Literature DB >> 34523070

Clinical characteristics and mortality rates for suprachoroidal hemorrhage: seven-year experience at a tertiary eye center.

Terry Lee1, Atalie C Thompson1, C Ellis Wisely1, Mitchell G Nash2, Eric A Postel1, Leon Herndon3.   

Abstract

PURPOSE: To investigate comorbidities and medications associated with acute (ASCH) and delayed (DSCH) suprachoroidal hemorrhage (SCH), and to explore visual outcomes and mortality following SCH.
METHODS: Retrospective review of SCH cases diagnosed at a tertiary center between 2013 and 2019. Demographics, history, surgery type, visual acuity, intraocular pressure (IOP), and mortality data were reviewed.
RESULTS: Fifty eyes of 50 patients experienced SCH related to surgery: 15 (30%) ASCH and 35 (70%) DSCH. Glaucoma surgery was the most common preceding surgery, and SCH was more likely to be delayed in glaucoma surgery relative to other surgeries (p = 0.001). The proportions of patients on anticoagulant, antiplatelet, or NSAID medications were 30% (n = 15), 52% (n = 26), and 12% (n = 6), respectively. The mean preoperative IOP was 25.0 ± 10.2 mmHg. The mean final best corrected visual acuity did not significantly differ between DSCH and ASCH (logMAR 1.92 vs. 2.36; p = 0.39). After controlling for pre-drainage visual acuity, final visual acuity was not statistically significantly different between eyes that were drained versus those that were not drained (p = 0.06). Of all 50 patients, the mortality rate was 12% with a mean time to mortality after SCH of 754 ± 564 days for those who died.
CONCLUSION: DSCH was more common than ASCH, with glaucoma surgery being the most common procedure to result in SCH. Visual outcomes and mortality rate were comparable between ASCH and DSCH. Further research is needed regarding the role of surgical drainage on improving visual outcomes in eyes with SCH.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Glaucoma; Mortality; Suprachoroidal hemorrhage; Visual outcomes

Mesh:

Year:  2021        PMID: 34523070     DOI: 10.1007/s00417-021-05290-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

1.  The pathology of expulsive hemorrhage.

Authors:  W A MANSCHOT
Journal:  Am J Ophthalmol       Date:  1955-07       Impact factor: 5.258

2.  Expulsive choroidal hemorrhage in rabbits. A histopathologic study.

Authors:  C F Beyer; G A Peyman; J M Hill
Journal:  Arch Ophthalmol       Date:  1989-11

3.  Penetrating keratoplasty and transscleral fixation of posterior chamber lens.

Authors:  E J Holland; S M Daya; A Evangelista; J M Ketcham; A J Lubniewski; D J Doughman; S S Lane
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

4.  Risk of acute suprachoroidal hemorrhage with phacoemulsification.

Authors:  A Eriksson; G Koranyi; S Seregard; B Philipson
Journal:  J Cataract Refract Surg       Date:  1998-06       Impact factor: 3.351

5.  Expulsive hemorrhage: some observations and comments.

Authors:  D M Taylor
Journal:  Trans Am Ophthalmol Soc       Date:  1974

6.  Perioperative choroidal hemorrhage at pars plana vitrectomy. A case-control study.

Authors:  J G Piper; D P Han; G W Abrams; W F Mieler
Journal:  Ophthalmology       Date:  1993-05       Impact factor: 12.079

7.  Massive suprachoroidal hemorrhage in penetrating keratoplasty.

Authors:  H J Ingraham; E D Donnenfeld; H D Perry
Journal:  Am J Ophthalmol       Date:  1989-12-15       Impact factor: 5.258

8.  Expulsive choroidal haemorrhage: an experimental study.

Authors:  H Zauberman
Journal:  Br J Ophthalmol       Date:  1982-01       Impact factor: 4.638

9.  Acute intraoperative suprachoroidal hemorrhage in extracapsular cataract surgery.

Authors:  J A Davison
Journal:  J Cataract Refract Surg       Date:  1986-11       Impact factor: 3.351

10.  Suprachoroidal hemorrhage after glaucoma filtering surgery.

Authors:  K Givens; M B Shields
Journal:  Am J Ophthalmol       Date:  1987-05-15       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.